US EditionPublished • loading... • Updated
Lilly to build $3 billion Dutch plant to boost weight-loss pill production
The $3 billion plant will create 500 skilled jobs and produce oral medicines for diabetes, obesity, cancer, and other chronic diseases, supporting growing European demand, Lilly said.
- Recently, Eli Lilly announced it will build a $3 billion plant at Leiden Bio Science Park in Katwijk, Netherlands.
- The plant will expand production of orforglipron and other oral medicines, Lilly says the move aims to meet growing European demand and speed regional distribution.
- Lilly said the site will create 500 skilled manufacturing jobs and about 1,500 construction jobs, with construction expected to start next year.
- Dutch economic officials welcomed the investment, with Vincent Karremans, Netherlands economic affairs minister, saying Katwijk was chosen after considering many locations and officials noting it will boost Leiden, Netherlands' economy and medicine innovation.
- Permits covering nitrogen, energy and accessibility remain pending amid debate over the Netherlands' business climate, including regulatory pressure, fiscal rules and energy costs.
Insights by Ground AI
24 Articles
24 Articles
"Katwijk is flying the flag, and Leiden has arranged the fanfare," says Jan Bart van der Plas of the Katwijk Business Association (KOV). The arrival of the large American pharmaceutical company Eli Lilly is being greeted with joy. Yet, there is also skepticism.
·Amsterdam, Netherlands
Read Full Article
The Netherlands Is Attractive for Pharmaceutical Companies. Katwijk Is Getting a Large Pill Factory.
The Netherlands is very attractive to pharmaceutical companies, especially since the European Medicines Agency (EMA) established itself here and with the development of Leiden Bio Science Park. Eli Lilly is now manufacturing weight-loss medications there, among other products.
·Netherlands
Read Full Article
Coverage Details
Total News Sources24
Leaning Left4Leaning Right3Center5Last UpdatedBias Distribution42% Center
Bias Distribution
- 42% of the sources are Center
42% Center
L 33%
C 42%
R 25%
Factuality
To view factuality data please Upgrade to Premium
